Predictive Technology Group, Inc. (OTCPK: PRED.Q)
Health Care · Biotechnology · US
$—
— today · — 1Y
Predictive Technology Group, Inc. (OTCPK: PRED.Q) operates in the Biotechnology industry within the Health Care sector. The company is valued at $317.00 and employs 62 people.
trading between 0.00 and 0.00.
Tweenvest scores Predictive Technology Group, Inc. across four factors: quality 54/100, value 55/100. Its strongest factor is value.
PRED.Q price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $317.00
- Revenue (TTM)
- $19.17M
- P/E
- —
- EPS
- -0.23
- Dividend yield
- —
- Beta (5Y)
- -0.44
- 52-week high
- $0.00
- 52-week low
- $0.00
- Avg volume (3M)
- —
- Shares outstanding
- 316.67M
- Employees
- 62
- Next earnings
- —
About Predictive Technology Group, Inc.
Predictive Technology Group, Inc., together with its subsidiaries, develops and commercializes discoveries and technologies involved in novel molecular diagnostic, therapeutic, and human cellular and tissue-based products (HCT/Ps). It operates in two segments, Human Cellular and Tissues Products (HCT/Ps); and Diagnostics and Therapeutics. The company provides FertilityDX, a genetic testing service for couples experiencing infertility; ARTguide, a genetic test for women experiencing infertility because of endometriosis and other genetic conditions; and regenerative medicine products, including AmnioCyte, AmnioCyte Plus, PolyCyte, and CoreCyte for use in regenerative medicine applications. It has a collaboration agreement with Atrin Pharmaceuticals LLC to develop molecular diagnostic tools to facilitate enhanced selection of cancer patients. The company was formerly known as Global Enterprises Group, Inc. and changed its name to Predictive Technology Group, Inc. in July 2015. Predictive Technology Group, Inc. was founded in 2005 and is headquartered in Salt Lake City, Utah.
- ISIN
- US74039H1023
- Founded
- 2005
- Listed since
- Jan 2, 2008
- Exchange
- Pink Sheets LLC
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $469.68B | $266.00 | +0.08% |
| Amgen Inc.NasdaqGS: AMGN | $239.09B | $442.45 | +0.05% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $184.47B | $148.74 | -0.02% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $140.13B | $552.00 | -0.15% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.24B | $832.63 | -0.11% |
| argenx SEENXTBR: ARGX | $64.17B | €909.60 | +3.46% |
| Moderna, Inc.NasdaqGS: MRNA | $63.41B | $156.05 | -1.75% |
| CSL LimitedASX: CSL | $59.49B | AU$173.64 | +2.68% |
Figures last refreshed Aug 18, 2026.